BioSpace News Archive

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023.

Grants to be awarded to early-career scientists for pioneering research in immunology, vaccine discovery, and immunotherapy research

PANTHERx®Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Edenbridge Pharmaceuticals for the distribution of Yargesa® (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that it will host a conference call and live webcast to provide a business update with certain financials for the year ending December 31, 2023 at 8:30 a.m. ET on Tuesday, April 2, 2024.

Ocugen, Inc. announced that the Data Safety and Monitoring Board for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of OCU410ST in the dose-escalation phase of the study.

Adcentrx Therapeutics (“Adcentrx”) today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.

ProPhase Labs, Inc., a next-generation biopharma, genomics, and diagnostics company, announced that it has granted an inducement stock option to purchase up to 50,000 shares of the Company’s common stock to Lance Bisesar, who recently joined the Company as Controller.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

PharmaJet® announced the formation of two Scientific Advisory Boards comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping.